BR0316991A - Compostos de anel de 1,3-diidro-imidazol fundido - Google Patents

Compostos de anel de 1,3-diidro-imidazol fundido

Info

Publication number
BR0316991A
BR0316991A BR0316991-0A BR0316991A BR0316991A BR 0316991 A BR0316991 A BR 0316991A BR 0316991 A BR0316991 A BR 0316991A BR 0316991 A BR0316991 A BR 0316991A
Authority
BR
Brazil
Prior art keywords
formula
denotes
substituents
fused
ring compounds
Prior art date
Application number
BR0316991-0A
Other languages
English (en)
Inventor
Kazunobu Kira
Richard Clark
Seiji Yoshikawa
Taisuke Uehara
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of BR0316991A publication Critical patent/BR0316991A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

"COMPOSTOS DE ANEL DE 1,3-DIIDRO-IMIDAZOL FUNDIDO". A presente invenção refere-se a compostos que mostram excelente atividade de inibição de DPPIV. A presente invenção fornece compostos representados pela fórmula geral (I), sais destes, ou hidratos destes, ¢na qual, T¬ 1¬ significa um heterociclo de 4 a 12 membros monocíclico ou bicíclico tendo 1 ou 2 átomos de nitrogênio no anel, que pode ter substituintes; na fórmula (I), a seguinte fórmula representa uma ligação dupla ou uma única ligação; X¬ 3¬ denota um átomo de oxigênio ou um átomo de enxofre; X¬ 1¬ denota um grupo de C~ 2-6, alquinila que pode ter substituintes; Z¬ 1¬ denota um átomo de nitrogênio ou a fórmula -CR¬ 3¬=; Z¬ 2¬ e Z¬ 3¬ cada qual independentemente denotam um átomo de nitrogênio, a fórmula -CR¬ 1¬=, um grupo de carbonila, ou a fórmula -NR¬ 2¬-; R¬ 1¬, R¬ 2¬, R¬ 3¬, eX¬ 2¬ cada qual independentemente denota um grupo de C~ 1-6~ alquila que pode ter substituintes, e similares.
BR0316991-0A 2002-12-04 2003-12-02 Compostos de anel de 1,3-diidro-imidazol fundido BR0316991A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002352186 2002-12-04
PCT/JP2003/015402 WO2004050656A1 (ja) 2002-12-04 2003-12-02 １，３−ジヒドロ−イミダゾール縮合環化合物

Publications (1)

Publication Number Publication Date
BR0316991A true BR0316991A (pt) 2005-10-25

Family

ID=32463216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316991-0A BR0316991A (pt) 2002-12-04 2003-12-02 Compostos de anel de 1,3-diidro-imidazol fundido

Country Status (17)

Country Link
US (1) US7524847B2 (pt)
EP (1) EP1568699A4 (pt)
JP (1) JP4279784B2 (pt)
KR (1) KR100867484B1 (pt)
CN (1) CN100376573C (pt)
AU (1) AU2003302657B8 (pt)
BR (1) BR0316991A (pt)
CA (1) CA2507763A1 (pt)
HK (1) HK1086556A1 (pt)
IL (1) IL168784A (pt)
MX (1) MXPA05005983A (pt)
NO (1) NO20053246L (pt)
NZ (1) NZ540495A (pt)
PL (1) PL377187A1 (pt)
RU (1) RU2328498C9 (pt)
WO (1) WO2004050656A1 (pt)
ZA (1) ZA200504973B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
RU2297418C9 (ru) 2002-06-06 2009-01-27 Эйсай Ко., Лтд. Новые конденсированные производные имидазола, ингибитор дипептидилпептидазы iv, фармацевтическая композиция, способ лечения и применение на их основе
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2006290205B2 (en) 2005-09-14 2012-12-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8796293B2 (en) * 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125320A1 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2009047563A1 (en) 2007-10-11 2009-04-16 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
JP5630867B2 (ja) * 2008-08-05 2014-11-26 第一三共株式会社 イミダゾピリジン−２−オン誘導体
US8901132B2 (en) * 2009-03-13 2014-12-02 Katholieke Universiteit Leuven, K.U. Leuven R&D Thiazolopyrimidine modulators as immunosuppressive agents
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
CN102153538B (zh) * 2010-02-11 2013-12-11 山东轩竹医药科技有限公司 苯并环衍生物
CN102276627B (zh) * 2010-04-29 2013-07-31 山东轩竹医药科技有限公司 吡啶并杂环衍生物
CN102234281B (zh) * 2010-04-29 2013-03-27 山东轩竹医药科技有限公司 嘧啶并环衍生物
PL2694056T3 (pl) 2011-04-01 2020-03-31 Astrazeneca Ab Leczenie terapeutyczne
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
MY175800A (en) 2011-11-30 2020-07-09 Astrazeneca Ab Combination treatment of cancer
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2015078799A1 (en) * 2013-11-27 2015-06-04 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
CN109608462B (zh) * 2018-12-15 2021-11-23 华南理工大学 一种7-烃基-9-烷氧/硫基嘌呤-8-酮类化合物及其合成方法与在药物中的应用
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
EP4267574A1 (en) 2020-12-23 2023-11-01 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87149A (en) * 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
JP2000086663A (ja) 1998-09-09 2000-03-28 Taisho Pharmaceut Co Ltd アリールテトラヒドロピリジン誘導体
AU756702B2 (en) 1999-03-11 2003-01-23 Taisho Pharmaceutical Co., Ltd. Carbamoyl tetrahydropyridine derivatives
JP2001151777A (ja) 1999-03-11 2001-06-05 Taisho Pharmaceut Co Ltd カルバモイルテトラヒドロピリジン誘導体
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
RU2297418C9 (ru) * 2002-06-06 2009-01-27 Эйсай Ко., Лтд. Новые конденсированные производные имидазола, ингибитор дипептидилпептидазы iv, фармацевтическая композиция, способ лечения и применение на их основе
MXPA05003252A (es) 2002-09-26 2005-07-05 Eisai Co Ltd Farmaco de combinacion.
AU2003284142A1 (en) * 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
JP4842829B2 (ja) 2003-10-31 2011-12-21 武田薬品工業株式会社 含窒素縮合複素環化合物
CA2554809C (en) * 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
EP1568699A1 (en) 2005-08-31
US7524847B2 (en) 2009-04-28
MXPA05005983A (es) 2005-08-18
AU2003302657B2 (en) 2009-09-24
HK1086556A1 (en) 2006-09-22
RU2005120780A (ru) 2006-01-20
ZA200504973B (en) 2006-04-26
AU2003302657A2 (en) 2004-06-23
NO20053246D0 (no) 2005-07-01
CN100376573C (zh) 2008-03-26
AU2003302657A1 (en) 2004-06-23
CN1745080A (zh) 2006-03-08
CA2507763A1 (en) 2004-06-17
KR20050087825A (ko) 2005-08-31
JP4279784B2 (ja) 2009-06-17
IL168784A (en) 2010-12-30
JPWO2004050656A1 (ja) 2006-03-30
KR100867484B1 (ko) 2008-11-06
RU2328498C2 (ru) 2008-07-10
AU2003302657B8 (en) 2009-12-03
RU2328498C9 (ru) 2008-12-10
EP1568699A4 (en) 2007-08-15
NZ540495A (en) 2007-09-28
NO20053246L (no) 2005-08-30
PL377187A1 (pl) 2006-01-23
US20060111362A1 (en) 2006-05-25
WO2004050656A1 (ja) 2004-06-17

Similar Documents

Publication Publication Date Title
BR0316991A (pt) Compostos de anel de 1,3-diidro-imidazol fundido
BR0311697A (pt) Novos derivados condensados de imidazol
BRPI0506817A (pt) inibidores seletivos de quinase
MX9206114A (es) Derivados de urea y proceso para su preparacion
BR0114436A (pt) Composto com anel de cinco elementos contendo nitrogênio alifático
BRPI0413991A (pt) composto ativador de ppar e composição farmacêutica contendo o mesmo
BRPI0509258A (pt) composto de 8-oxoadenina 9-substituìda
BRPI0514644A (pt) composto fosforamidita, composto ácido ribonucléico, e método para produzir oligo-rna
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
BR9911048A (pt) Inibidor de spla2 de pirrolo[1,2-b]piridazina
BRPI0606480A (pt) compostos farmacêuticos
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
BR0206670A (pt) Compostos halogenados que exibem agonismo para receptor de trombopoietina
BR0108303A (pt) Derivados do 1h-imidazopiridina
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR0309522A (pt) Compostos piridina ou sais destes e herbicidas contendo os mesmos
ATE273305T1 (de) Thrombin-inhibitoren
DOP2006000060A (es) Compuestos de n-sulfonilaminofeniletil -2-fenoxiacetamida sustituida
TW200612920A (en) Novel imidazolidine derivatives
DK1436257T3 (da) Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning
DK0888271T3 (da) Benzamidinderivater substitueret med aminosyre- og hydroxysyrederivater og deres anvendelse som antikoagulerende midler
BRPI0509095A (pt) método para produzir um composto aminofenol
TW200710173A (en) Nitrosulfide dyes
BR0311410A (pt) Composto de piperidina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP)

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.